查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2152392

口蹄疫疫苗市場規模、佔有率和趨勢分析報告：按目標動物、疫苗、分銷管道、地區和細分市場預測（2026-2033 年）

Foot And Mouth Disease Vaccine Market Size, Share & Trends Analysis Report By Animal (Cattle, Sheep & Goat, Swine), By Vaccine (Modified/Attenuated Live), By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

全球口蹄疫疫苗市場預計到 2025 年將達到 27 億美元，到 2026 年將擴大到 29 億美元，到 2033 年將達到 51 億美元，2026 年至 2033 年的複合年成長率約為 8.8%。

亞太地區是推動市場成長的主要力量，預計到2025年將佔全球銷售額的45.0%。牲畜數量的增加和對畜產品需求的成長是促進市場成長的關鍵因素。此外，過去幾十年來，快速的全球化和氣候變遷導致牲畜疾病的增加。各國政府正在實施各種措施和計劃，以確保伴侶動物和牲畜的健康安全。這促進了獸用疫苗市場的成長，其中口蹄疫疫苗佔據了相當大的佔有率。

隨著人口成長，對牛奶、家禽、雞蛋和肉類等動物產品的需求也不斷增加。疫苗有助於最大限度地減少牲畜損失並確保其安全，預計這將推動預測期內的市場成長。印度等國家牛奶和乳製品產量及消費量的成長預計也將進一步促進市場成長。

在開發中國家，畜牧業是國內生產毛額的重要組成部分，這導致對高效動物保健措施的需求不斷成長，預計這將推動預測期內市場成長。例如，根據印度財政部2024年7月發布的信息，2022-2023會計年度畜牧業佔增加值總額（GVA）的4.6%，從而提高了人均牛奶、雞蛋和肉類供應量。由於引入了先進的藥物和疫苗接種計劃來維護牲畜健康，牲畜數量正在迅速成長。

多項政府措施和計劃正在推動該市場的成長。據美國食品和農業部以及世界動物衛生組織（OIE）稱，「2021-2025年東南亞口蹄疫控制和根除計畫」（SEACFMD 2021-2025）旨在透過控制和根除口蹄疫，提高畜牧業的生產力和經濟產出，從而加強糧食安全並支持農村地區的小規模農戶。政府投資推出了口蹄疫疫苗的生產，並促進了市場成長。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：口蹄疫疫苗市場：變數、趨勢與範圍

  • 市場概況及未來展望
  • 市場規模和成長前景
  • 市場動態
  • 口蹄疫疫苗市場分析工具

第4章：口蹄疫疫苗市場：依動物種類分類的估算與趨勢分析

  • 口蹄疫疫苗市場：動物流動分析，2025 年和 2033 年
  • 牛
  • 綿羊和山羊
  • 豬
  • 其他

第5章：口蹄疫疫苗市場：依疫苗類型分類的估算與趨勢分析

  • 口蹄疫疫苗市場：按疫苗類型分類的2025年和2033年變化分析
  • 改良/減毒活病毒疫苗
  • 失活（殺死）
  • 其他疫苗（DNA疫苗、胜肽疫苗）

第6章：口蹄疫疫苗市場：按通路分類的估算與趨勢分析

  • 口蹄疫疫苗市場：按分銷管道分類的趨勢分析（2025 年和 2033 年）
  • 獸醫醫院和診所
  • 政府機構
  • 其他

第7章：口蹄疫疫苗市場：區域估算與趨勢分析

  • 2025 年和 2033 年口蹄疫疫苗區域市場佔有率
  • 歐洲
    • 俄羅斯
    • 法國
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 印尼
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特
    • 埃及
    • 土耳其

第8章 競爭情勢

  • 主要市場參與企業近期趨勢及影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Merck & Co., Inc.
    • Biogenesis Bago
    • Zoetis Inc.
    • Boehringer Ingelheim International GmbH
    • Indian Immunologicals Limited
    • Bayer AG
    • Hester Biosciences Limited
    • Inner Mongolia Biwei Antai Biotechnology Co., Ltd.
    • Brilliant Bio Pharma Limited
    • Biovet Private Ltd
簡介目錄
Product Code: GVR-1-68038-656-1

The global foot and mouth disease vaccine market was valued at USD 2.7 billion in 2025 and is projected to grow from USD 2.9 billion in 2026 to USD 5.1 billion in 2033, at a CAGR of approximately 8.8% from 2026 to 2033. The Asia Pacific dominated the market, accounting for a revenue share of 45.0% in 2025. The increasing livestock population and demand for animal products are significant factors contributing to market growth. In addition, with rapid globalization and climate change, livestock diseases have been increasing over the past few decades. To ensure safe healthcare practices for companion animals and livestock, the government has undertaken various initiatives and programs. Thereby, contributing to the growth of the veterinary vaccine market, of which foot and mouth disease (FMD) vaccines capture a significant share.

The growing human population has driven the demand for animal products such as milk, chicken, eggs, and meat. Vaccines help minimize animal loss and ensure their safety, which is likely to drive market growth over the forecast period. The increasing production and consumption of milk and milk products in countries such as India are further expected to contribute to market growth.

In developing countries, livestock is a contributor to GDP; hence, there is increasing demand for efficient animal healthcare practices, which is expected to drive growth in this market over the forecast period. For instance, in July 2024, according to information published by the Ministry of Finance (India), 4.6% of total GVA in 2022-23 was contributed by the livestock sector, thereby boosting the per capita availability of milk, eggs, and meat. The livestock population has increased rapidly owing to the adoption of advanced medication and vaccination programs to maintain livestock health.

Various government initiatives and programs have boosted growth in this market. According to the Food and Agriculture Organization of the U.S. and the World Organization for Animal Health, SEACFMD 2021-2025 was launched to increase productivity and economic output in the livestock sector by managing and eradicating FMD, thereby enhancing food security and supporting rural smallholder farmers. Investments made by government institutions have supported the production of FMD vaccines and boosted the market growth.

Global Foot And Mouth Disease Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global foot and mouth disease vaccine market report based on animal, vaccine, distribution channel, and region:

  • Animal Outlook (Revenue, USD Billion, 2021 - 2033)

Cattle

Sheep and Goat

Swine

Others

  • Vaccine Outlook (Revenue, USD Billion, 2021 - 2033)

Modified/ Attenuated Live

Inactivated (Killed)

Other Vaccines

  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)

Veterinary Hospitals & Clinics

Government Institutions

Others

  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)

Europe

    • Russia
    • France

Asia Pacific

    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand

Latin America

    • Brazil
    • Argentina

MEA

    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Egypt
    • Turkey

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Foot & Mouth Disease Vaccine Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Foot & Mouth Disease Vaccine Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Foot & Mouth Disease Vaccine Market: Animal Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Foot & Mouth Disease Vaccine Market: Animal Movement Analysis, 2025 & 2033 (USD Million)
  • 4.3. Cattle
    • 4.3.1. Cattle Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Sheep and Goat
    • 4.4.1. Sheep and Goat Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Swine
    • 4.5.1. Swine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Foot & Mouth Disease Vaccine Market: Vaccine Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Foot & Mouth Disease Vaccine Market: Vaccine Movement Analysis, 2025 & 2033 (USD Million)
  • 5.3. Modified/ Attenuated Live
    • 5.3.1. Modified/ Attenuated Live Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Inactivated (Killed)
    • 5.4.1. Inactivated (Killed) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Other Vaccines (DNA vaccines, Peptide vaccines)
    • 5.5.1. Other Vaccines (DNA vaccines, Peptide vaccines) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Foot & Mouth Disease Vaccine Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Foot & Mouth Disease Vaccine Market: Distribution Channel Movement Analysis, 2025 & 2033 (USD Million)
  • 6.3. Veterinary Hospitals & Clinics
    • 6.3.1. Veterinary Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Government Institutions
    • 6.4.1. Government Institutions Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Foot & Mouth Disease Vaccine Market: Regional Estimates & Trend Analysis

  • 7.1. Foot & Mouth Disease Vaccine Market Share, By Region, 2025 & 2033 (USD Million)
  • 7.2. Europe
    • 7.2.1. Europe Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.2. Russia
      • 7.2.2.1. Russia Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.3. France
      • 7.2.3.1. France Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3. Asia Pacific
    • 7.3.1. Asia Pacific Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. Japan
      • 7.3.2.1. Japan Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. China
      • 7.3.3.1. China Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. India
      • 7.3.4.1. India Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.5. South Korea
      • 7.3.5.1. South Korea Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.6. Indonesia
      • 7.3.6.1. Indonesia Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.7. South Korea
      • 7.3.7.1. South Korea Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.8. Thailand
      • 7.3.8.1. Thailand Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Latin America
    • 7.4.1. Latin America Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Brazil
      • 7.4.2.1. Brazil Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Argentina
      • 7.4.3.1. Argentina Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Middle East and Africa
    • 7.5.1. Middle East and Africa Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. South Africa
      • 7.5.2.1. South Africa Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Saudi Arabia
      • 7.5.3.1. Saudi Arabia Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. UAE
      • 7.5.4.1. Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Kuwait
      • 7.5.5.1. Kuwait Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Egypt
      • 7.5.6.1. Egypt Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Turkey
      • 7.5.7.1. Turkey Foot & Mouth Disease Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Merck & Co., Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Biogenesis Bago
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Zoetis Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Boehringer Ingelheim International GmbH
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Indian Immunologicals Limited
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Bayer AG
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Hester Biosciences Limited
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Inner Mongolia Biwei Antai Biotechnology Co., Ltd.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Brilliant Bio Pharma Limited
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Biovet Private Ltd
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives